首頁/MCK

公开研究页

行情来自市场数据接口；下方公司研究基于已核验公开来源，但不等同于实时、个性化的 AI 投资结论。

去工作台分析 MCK
MCKNYSE/health care

McKesson Corporation

$812.28上涨+6,32 (+0,78%)
研究复核截至: 2026年7月12日 上午12:00 [UTC]
研究概览近 3 个月价格投资论点关键催化剂最新财报研究近期新闻数据与研究来源

研究概览

McKesson Corporation operates in Health Care Distributors within the health care sector. This profile tracks its company-specific earnings drivers, valuation conditions, and primary-source risks.

Открытие
812,87
Максимум
822,38
Минимум
806,24
Капитализация
95,1 млрд
P/E
21.18
Максимум за 52 недели
--
Дивиденд
0.410%
Квартальный дивиденд
--

近 3 个月价格

這裡展示近 3 個月價格走勢，幫助使用者先理解短期結構，再決定是否進入完整研究工作台。

投资论点

基础情景
Growth in complex medicines can increase distribution, provider-services and data demand. The base case remains conditional on customer concentration staying manageable.
多头情景
Growth in complex medicines can increase distribution, provider-services and data demand. The US Oncology Network and related services can deepen relationships with community practices and manufacturers. Strong cash conversion can fund repurchases and targeted investment in higher-growth health platforms.
空头情景
Large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk. Reimbursement, pricing and distribution reforms can alter volumes, working capital and service economics. Controlled-substance obligations and healthcare compliance failures can create litigation and remediation costs.
论点失效条件
Reassess the thesis if large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk.

关键催化剂

  • Specialty distribution

    Growth in complex medicines can increase distribution, provider-services and data demand.

  • Oncology ecosystem

    The US Oncology Network and related services can deepen relationships with community practices and manufacturers.

  • Capital allocation

    Strong cash conversion can fund repurchases and targeted investment in higher-growth health platforms.

主要风险

  • Customer concentration

    Large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk.

  • Drug-policy change

    Reimbursement, pricing and distribution reforms can alter volumes, working capital and service economics.

  • Legal and compliance

    Controlled-substance obligations and healthcare compliance failures can create litigation and remediation costs.

最新财报研究

FY2026 Q4

McKesson's fiscal fourth-quarter 2026 update reflected resilient pharmaceutical distribution, oncology-platform growth and continued portfolio focus, supported by cash generation and disciplined capital allocation.

估值解读

  • Distribution scale supports durable cash flow, while oncology and specialty services determine the mix-improvement opportunity.
  • Thin distribution margins require valuation discipline around working capital, customer concentration and policy change.

同行比较入口

ABBVJNJLLY

近期新闻

Zacks · 9 часов назад

5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds

Simply Wall St. · позавчера

McKesson (MCK) Falls After CEO Share Sale, Is The 14% Discount Enough?

Simply Wall St. · 3 дня назад

Can McKesson (MCK) Stay Cheap After A 338% Five Year Run?

Simply Wall St. · 3 дня назад

McKesson (MCK) CEO Sells Shares As Company Names A New Strategy Chief

StockStory · 4 дня назад

McKesson (MCK) Stock Trades Down, Here Is Why

Zacks · 4 дня назад

Should You Retain CAH Stock After Removal From Several Russell Indices?

数据与研究来源

研究更新: 2026年7月12日 上午12:00 [UTC]
3 个已核验来源
McKesson Reports Fiscal 2026 Fourth-Quarter ResultsMcKesson Corporation · earnings已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/5/7 上午12:00:00

查看原始来源
McKesson Corporation Investor RelationsMcKesson Corporation · company已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

查看原始来源
McKesson SEC filings and company factsU.S. Securities and Exchange Commission · filing已核验

抓取时间: 2026/7/12 上午12:00:00 [UTC]

发布时间: 2026/5/7 上午12:00:00

查看原始来源

在工作台中继续研究

保留 MCK，运行多智能体分析并持续跟踪论点变化。

免费分析 MCK

探索完整研究體系

每個階段職責明確，並為下一階段留下可追溯的輸出。

研究方法論閱讀市場報告瀏覽股票

继续深挖这只股票

市場分析 Agent

負責先判断价格結構、趋势强弱與交易節奏有没有支持 thesis。

基本面分析 Agent

負責判断公司的业务质量、盈利結構與财务健康度。

新闻分析 Agent

追踪最近发生了什么，以及這些事件是否真的改变 thesis。

風險经理 Agent

負責在風險辩論后给出最终風險等級和执行邊界。